The Memo: GelSana Advancing a New Class of Polymers for Chronic Wound Healing

Under the direction of Founder and CEO Melissa Krebs, PhD, GelSana is developing a novel class of synthetic polymers designed to address two of the most persistent barriers in chronic wound healing: inflammation and infection. Built on more than a decade of biomaterials research, the company’s technology is engineered to help calm inflammation, repel bacteria, and create an optimal environment for wound healing. With strong preclinical results, nearly $6 million raised to date, and its first product, CleraFlex™ Stretchable Wound Dressing, expected to launch imminently, GelSana is entering a large and rapidly evolving wound care market with a fundamentally new materials platform.

Origin Story

GelSana’s technology originated in the academic lab of Melissa Krebs, PhD, who has spent her career researching biomaterials and translational medical technologies. The polymers that now form the foundation of GelSana were developed and refined in her lab over more than a decade.

“I’ve been doing biomaterials research my whole career,” Krebs explained. “But the products that ultimately became GelSana started in my lab at the Colorado School of Mines more than ten years ago.”

The company itself emerged from an unexpected opportunity. In 2020, Krebs began discussions with a local VC fund in Colorado about the underlying technology. At the time, she was not actively planning to start a company.

“In September 2020, they offered me pre-seed funding to start a company,” she recalled. “That’s when I decided to take the step. I founded GelSana, spun the technology out of my university lab, and licensed the IP from the university into the company.”

The scientific foundation was already well established. Years of research had produced extensive material development data alongside early preclinical validation.

“We had already generated a lot of in vitro data and completed the core material development,” Krebs said. “We were also seeing very promising results in early animal studies showing improved wound healing.”

That body of research gave GelSana a strong starting point, allowing the company to launch with both a differentiated materials platform and encouraging early evidence of clinical potential.

The Current Landscape

Chronic wounds remain one of the most costly, difficult, and often overlooked challenges in healthcare. These wounds, including diabetic foot ulcers, are characterized by persistent inflammation that prevents the body’s natural healing processes from progressing.

Existing wound dressings often focus on protecting the wound or managing moisture. However, they do not directly address the underlying environment that can stall healing in instances where there is too much inflammation, and the wound cannot transition out of this inflammatory phase.

The scale of the problem is enormous. Diabetic ulcers alone are estimated to cost $78 billion annually in the United States. They account for roughly 80% of non-traumatic amputations, and globally, a limb is lost every 20 seconds due to a non-healing diabetic ulcer.

At the same time, the wound care market is undergoing significant change. Krebs noted that shifts in reimbursement policies are creating a window for new technologies.

“The wound care market is notoriously competitive,” she said. “But we’re entering with a completely new material at a time when reimbursement dynamics are shifting significantly.”

Traditionally, many advanced wound therapies have relied on expensive skin substitutes and other cellular and tissue-based products. Recent Medicare reimbursement changes are placing stricter limits on these high-cost therapies, creating an opening for new technologies to enter the market.

“We see this as an opportunity to introduce a first-line-of-care product for patients,” Krebs explained. “It’s a highly innovative technology entering a market that has seen little innovation in decades.”

This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/the-memo-gelsana-advancing-a-new-class-of-polymers-for-chronic-wound-healing